Prescient Therapeutics Ltd has released a press release.
PTX-100 progresses to new dose, adds new site
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- March 2020 Quarterly Update and Appendix 4C
- December 2019 Appendix 4C - Quarterly
- PTX-200 High Overall Response in Ph2a Breast Cancer trial
- Encouraging data from PTX-200 ovarian cancer trial
- Third complete response in PTX-200 AML Trial
Later from Prescient Therapeutics
- Pause in Trading
- Voluntary Suspension
- PTX signs next-gen anti-cancer platform from Penn & Oxford
- Reinstatement to Official Quotation
- Trading Pause
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics